My HPRA: Register

Direct Healthcare Professional Communications (DHPCs) - Issued in September 2017

Notice type: 3rd Party Publications

Date: 02/10/2017

Please find below the Direct Healthcare Professional Communications (DHPCs) issued in September 2017

Human Epoetins: Important Safety Information from the Marketing Authorization Holders (MAHs) of all epoetins as approved by the HPRA
Dacogen (decitabine) - Important Safety Information from Janssen-Cilag Limited as approved by the HPRA

Humalog (insulin lispro) - Important Safety Information from Eli Lilly and Co (Ireland) Limited as approved by the HPRA (Sept 2017)

Target Audience:
Healthcare Professionals

« Back

Important information regarding cookies and the HPRA

By using this website, you consent to the use of cookies in accordance with the HPRA Cookie Policy.
For more information on cookies, see our cookie policy.

Click here to accept the cookie policy and hide this message